國家衛生研究院 NHRI:Item 3990099045/7573
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 856867      在线人数 : 948
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/7573


    题名: Development drug candidate targeting EGFR kinase: DBPR112
    作者: Sun, HY;Hsu, JTA;Chen, CT;Yeh, TK;Pan, SL;Chao, YS;Hsieh, HP
    贡献者: Institute of Biotechnology and Pharmaceutical Research
    摘要: Lung cancer is the major cause of cancer death in the world while non small cell lung cancer (NSCLC) accounts approximately 85% of all lung cancer diagnosis. EGFR mutations, found in 10-30% of patients with NSCLC characterize a subpopulation with exquisite sensitivity to EGFR tyrosine kinase inhibitors (EGFR-TKIs). However, the clinical benefits of first-generation TKIs (like gefitinib) can be further improved because of the development of drug-acquired resistance within 10-14 months in patients who initially respond to the treatment. Therefore, there is a need to discover next generation medicines as EGFR-TKIs for NSCLC patients.Currently, we had identified DBPR112 as a potent EGFR-TKI with oral in vivo activity in a mouse model for lung adenocarcinoma. DBPR112 showed IC50 of 2 nM in HCC827 cells and potent EGFR Wild-Type (IC50: 10 nM) and EGFRL858R/T790M (IC50: 70 nM) kinase inhibition which are better than gefitinib and similar to that of BIBW2992 (afatinib, developed by Boehringer Ingelheim) that is currently under phase III clinical trial. DBPR112 was orally administered against the growth of human lung HCC827 tumors subcutaneously xenografted in nude mice. A dramatic reduction of the tumor size was noted in the tumors treated with DBPR112 without significant loss of body weights in the nude mice. In addition, the pharmacokinetics properties of DBPR112 are superior to those of BIBW2992. These results demonstrate the potential of DBPR112 as a therapeutic candidate for the treatment of lung adenocarcinoma with EGFR mutations.
    日期: 2013-04-07
    關聯: Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 299-MEDI.
    Link to: http://abstracts.acs.org/chem/245nm/program/view.php?pub_num=299&par=MEDI
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000324303602318
    显示于类别:[謝興邦] 會議論文/會議摘要
    [趙宇生(2002-2013)] 會議論文/會議摘要
    [葉燈光] 會議論文/會議摘要
    [潘秀玲(2009-2013)] 會議論文/會議摘要
    [徐祖安] 會議論文/會議摘要
    [陳炯東] 會議論文/會議摘要

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000324303602318.pdf376KbAdobe PDF640检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈